Local chemotherapy with interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma

Blasi, Maria Antonietta; Gherlinzoni, Filíppo; Calvisi, Giuseppe; Sasso, Paola; Tani, Monica; Cellini, Mauro; Balestrazzi, E.

doi:10.1016/s0161-6420(00)00591-1

Cited by 69 publications

(41 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies in the literature have shown success with other treatment modalities. Blasi et al demonstrated superficial conjunctival MALT lymphoma to be responsive to subconjunctival injections of local chemotherapy using interferon-alpha [9] and Ben Simon et al reported cases of isolated orbital MALT lymphoma responsive to systemic chemotherapy using oral chlorambucil [10]. …”

Section: Commentsmentioning

confidence: 99%

A case of an enlarged medial rectus muscle

2008

View full text Add to dashboard Cite

show abstract

Section: Commentsmentioning

confidence: 99%

A case of an enlarged medial rectus muscle

2008

View full text Add to dashboard Cite

show abstract

“…Subconjunctival intralesional injections of interferon-α were tried in a small group of patients, with promising results [119,132]. Recently, a pilot study of C. psittaci-eradicating therapy in patients with ocular MALT lymphoma was undertaken by the Italian group that initially published data on the association between the two entities [133].…”

Section: Ocular Adnexa and Lacrimal Glandmentioning

confidence: 99%

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Blasi et al 94 reported 5 patients with conjunctival MALT lymphoma treated with 1 500 000 IU IFN-␣ injected subconjunctivally inside the lesion 3 times a week for 4 weeks. Complete response was obtained BLOOD, 1 SEPTEMBER 2006 ⅐ VOLUME 108, NUMBER 5…”

Section: Immunotherapy Of Oalmentioning

confidence: 99%

Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options

Decaudin

Crémoux

Vincent‐Salomon

et al. 2006

Blood

133

View full text Add to dashboard Cite

IntroductionLymphoproliferations of the eye, including intraocular and ocular adnexal non-Hodgkin lymphoma (NHL), constitute a heterogeneous group of neoplasms that represent less than 1% of all NHLs 1 and 5% to 15% of all extranodal sites. 2 First described in 1952, 3 they are the most frequent malignant tumors of the eye and ocular adnexae; in fact, in the Florida cancer registry, they represent up to 55% of all orbital tumors. 4 As for all NHLs, a marked increase of the incidence of ocular adnexal NHL has also been observed. 4 The clinical features and natural history of ocular adnexal lymphoma (OAL) is completely different from those of intraocular lymphoma, which emphasizes the need to distinguish between the therapeutic management of both. Intraocular lymphoma is a subset of primary central nervous system lymphoma, 5-7 and intraocular involvement is found in approximately 15% of affected patients. 8 The histologic subtype of intraocular lymphoma is almost always high grade 9,10 and it can occur in the context ofAIDS-related lymphoproliferations. In contrast, OALs-including lesions of the conjunctiva, lacrimal gland, orbit, and eyelids-are mainly low-grade tumors not associated with HIV infection. 11 Although combination chemotherapy with highdose methotrexate is the basis of treatment of primary central nervous system and intraocular lymphomas, 10,12 radiotherapy has been the standard treatment for low-grade ophthalmologic lymphomas. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] However, other treatment options, such as therapy with monoclonal anti-CD20 antibody, 31,32 may constitute a promising alternative to external beam irradiation and its potential toxicity. In addition, some reports have suggested a possible value of anti-Chlamydia psittaci antibiotic therapy. 33,34 In this review, which is exclusively focused on ophthalmologic lymphomas, we first present the pathologic, clinical, and prognostic factors of these lymphomas and then discuss all available treatment options in terms of safety and efficacy and their respective indications. Biology of ophthalmologic lymphomas Diagnosis of OALAs for all other forms of nodal and extranodal NHL, confirming a positive diagnosis of OAL is often long and difficult because the tumor is very small in most patients. Positive diagnosis must be based on histologic examination of a sufficient tumor sample obtained by surgical biopsy that is large enough to allow rigorous definition of lymphoproliferative disease according to the World Health Organization (WHO) classification. 35 Histopathologic examination consists of morphologic examination of cellular proliferation (cellular appearance and architectural pattern), usually combined with immunohistochemical analysis and molecular analysis.The exact modalities of biopsy depend on the anatomic site of the lesion and its relation to the eye: biopsy may be performed of the conjunctiva, an eyelid lesion, an orbital mass, or the lacrimal gland. However, sometimes patients have nodal involvement, an...

show abstract

Local chemotherapy with interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma

Cited by 69 publications

References 7 publications

A case of an enlarged medial rectus muscle

A case of an enlarged medial rectus muscle

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options

Contact Info

Product

Resources

About